U.K. Announces Recall of Adrenaline Pens

March 4, 2020

A Bausch & Lomb affiliate has recalled all unexpired batches of its Emerade 150 microgram auto-injecting pens, citing a component error that could cause the pens not to deliver adrenaline, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) said.

The devicemaker, PharmaSwiss Česka Republika, directed healthcare providers to replace the autoinjectors with an alternative brand. The licensed dosing recommendations differ between brands, the company noted.

Testing of the recalled products revealed that approximately 13 percent of them require greater force to activate, which could cause them to fail.

View today's stories